Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.43 |
| ▸ | CDK2 | P24941 | 7/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.39 |
| ▸ | STK10 | O94804 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | MARK3 | P27448 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PSMC4 | P43686 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22945192 | 0.91 | CHEK1 (0.48) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL17940604 | 0.89 | SLC18A3 (0.44) | CHEK1CCNA2CDK2CCNA1HCAR2 | |
| Hydrochloric Acid SCHEMBL2885168 | 0.87 | SLC18A3 (0.42) | CHEK1CCNA2CDK2CCNA1HCAR2 | |
| SCHEMBL25841555 | 0.86 | PIM1 (0.42) | CHEK1CCNA2CDK2CCNA1HCAR2 | |
| SCHEMBL22886458 | 0.85 | HCAR2 (0.43) | CHEK1CCNA2CDK2CCNA1HCAR2 | |
| SCHEMBL22515514 | 0.83 | HTR3A (0.40) | HTR3ACHEK1CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL31644282 | 0.83 | HCAR2 (0.42) | CHEK1CCNA2CDK2CCNA1HCAR2 | |
| SCHEMBL21743172 | 0.81 | HTR3A (0.41) | HTR3ACHRM2CHRM3 | |
| SCHEMBL11918951 | 0.81 | HTR3A (0.41) | HTR3ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL21743281 | 0.81 | HTR3A (0.41) | HTR3ACHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| WO-2024026423-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS PI3K INHIBITORS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-08-11 | — | — | US | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | HTR3A 4577/4885CHEK1 349/4885CCNA2 873/4885 |
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | HTR3A 3838/4885CHEK1 363/4885CCNA2 4316/4885 |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | HTR3A 4579/4885CHEK1 869/4885CCNA2 1800/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | HTR3A 4666/4885CHEK1 275/4885CCNA2 801/4885 |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | HTR3A 3011/4885CHEK1 281/4885CCNA2 882/4885 |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | HTR3A 1400/4885CHEK1 199/4885CCNA2 425/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | HTR3A 3918/4885CHEK1 415/4885CCNA2 2401/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | HTR3A 4577/4885CHEK1 349/4885CCNA2 873/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | HTR3A 4577/4885CHEK1 349/4885CCNA2 873/4885 |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | HTR3A 549/4885CHEK1 2557/4885CCNA2 3215/4885 |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | HTR3A 4507/4885CHEK1 858/4885CCNA2 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.